Targeted gene therapy of autoimmune diseases: advances and prospects
- 1 September 2005
- journal article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 1 (3) , 385-404
- https://doi.org/10.1586/1744666x.1.3.385
Abstract
Idealized gene therapy of autoimmune diseases would mean getting the right drug to the right place at the right time to affect the right mechanism of action. In other words, a specific gene therapy strategy needs to have functional, spatial and temporal specificity. Functional specificity implies targeting the cellular, molecular and/or genetic mechanisms relevant to the disease, without affecting nondiseased organs or tissues through mechanisms that cause adverse effects. Spatial specificity means the delivery of the therapeutic agent exclusively to sites and cells that are relevant to the disease. Temporal specificity is, in principle, synonymous with controlled on-demand expression of the therapeutic gene and thus represents a major safety feature. This article reviews recent advances in strategies to use gene therapy in the treatment of autoimmune diseases.Keywords
This publication has 125 references indexed in Scilit:
- Antiangiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vectorGene Therapy, 2004
- Gene therapy for autoimmune diseases: quo vadis?Nature Reviews Immunology, 2004
- Transactivator and Structurally Optimized Inducible Lentiviral VectorsMolecular Therapy, 2004
- Role of dendritic cells in the generation of regulatory T cellsSeminars in Immunology, 2004
- A nonviral carrier for targeted gene delivery to tumor cellsCancer Gene Therapy, 2003
- In VivoLigand-Inducible Regulation of Gene Expression in a Gutless Adenoviral Vector SystemHuman Gene Therapy, 2003
- Immunopathology and the gene therapy of lupusGene Therapy, 2003
- Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytesGene Therapy, 2003
- Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytesNature Biotechnology, 2002
- C3‐Tat/HIV–regulated intraarticular human interleukin‐1 receptor antagonist gene therapy results in efficient inhibition of collagen‐induced arthritis superior to cytomegalovirus‐regulated expression of the same transgeneArthritis & Rheumatism, 2002